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A B S T R A C T
Background
Eczema is an inflammatory skin disease that tends to involve skin creases, such as the folds of the elbows or knees; it is an intensely
itchy skin condition, which can relapse and remit over time. As many as a third of people with eczema who have a positive test for
allergy to house dust mite have reported worsening of eczema or respiratory symptoms when exposed to dust.
Objectives
To assess the effects of all house dust mite reduction and avoidance measures for the treatment of eczema.
Search methods
We searched the following databases up to 14 August 2014: the Cochrane Skin Group Specialised Register, CENTRAL in The Cochrane
Library (2014, Issue 8), MEDLINE (from 1946), Embase (from 1974), LILACS (from 1982), and the GREAT database. We also
searched five trials registers and checked the reference lists of included and excluded studies for further references to relevant studies.
We handsearched abstracts from international eczema and allergy meetings.
Selection criteria
Randomised controlled trials (RCTs) of any of the house dust mite reduction and avoidance measures for the treatment of eczema,
which included participants of any age diagnosed by a clinician with eczema as defined by theWorld AllergyOrganization. We included
all non-pharmacological and pharmacological interventions that sought to reduce or avoid exposure to house dust mite and their
allergenic faeces. The comparators were any active treatment, no treatment, placebo, or standard care only.
Data collection and analysis
Two authors independently checked the titles and abstracts identified, and there were no disagreements. We contacted authors of
included studies for additional information. We assessed the risk of bias using Cochrane methodology.
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Main results
We included seven studies of 324 adults and children with eczema. Overall, the included studies had a high risk of bias. Four of the
seven trials tested interventions with multiple components, and three tested a single intervention. Two of the seven trials included only
children, four included children and adults, and one included only adults. Interventions to reduce or avoid exposure to house dust
mite included covers for mattresses and bedding, increased or high-quality vacuuming of carpets and mattresses, and sprays that kill
house dust mites.
Four studies assessed our first primary outcome of ’Clinician-assessed eczema severity using a named scale’. Of these, one study (n = 20)
did not show any significant short-term benefit from allergen impermeable polyurethane mattress encasings and acaricide spray versus
allergen permeable cotton mattress encasings and placebo acaricide spray. One study (n = 60) found a modest statistically significant
benefit in the Six Area, Six Sign AtopicDermatitis (SASSAD) scale over six months (mean difference of 4.2 (95% confidence interval 1.7
to 6.7), P = 0.008) in favour of a mite impermeable bedding system combined with benzyltannate spray and high-filtration vacuuming
versus mite permeable cotton encasings, water with a trace of alcohol spray, and a low-filtration vacuum cleaner. The third study (n
= 41) did not compare the change in severity of eczema between the two treatment groups. The fourth study (n = 86) reported no
evidence of a difference between the treatment groups.
With regard to the secondary outcomes ’Participant- or caregiver-assessed global eczema severity score’ and the ’Amount and frequency
of topical treatment required’, one study (n = 20) assessed these outcomes with similar results being reported for these outcomes in
both groups. Four studies (n = 159) assessed ’Sensitivity to house dust mite allergen using a marker’; there was no clear evidence of a
difference in sensitivity levels reported between treatments in any of the four trials.
None of the seven included studies assessed our second primary outcome ’Participant- or caregiver-assessed eczema-related quality of
life using a named instrument’ or the secondary outcome of ’Adverse effects’.
We were unable to combine any of our results because of variability in the interventions and paucity of data.
Authors’ conclusions
We were unable to determine clear implications to inform clinical practice from the very low-quality evidence currently available. The
modest treatment responses reported were in people with atopic eczema, specifically with sensitivity to one or more aeroallergens. Thus,
their use in the eczema population as a whole is unknown. High-quality long-term trials of single, easy-to-administer house dust mite
reduction or avoidance measures are worth pursuing.
P L A I N L A N G U A G E S U M M A R Y
House dust mite reduction and avoidance measures for treating eczema
Background
Eczema is an intensely itchy skin disease that tends to involve skin creases, such as the folds of the elbows or knees. It is a worldwide
problem affecting 5% to 20% of children. Around 2% of adults have the condition, and many have a more chronic and severe form.
As many as a third of people with eczema who have a positive test for allergy to house dust mite have reported worsening of eczema
or respiratory symptoms when exposed to dust. Ways to reduce or avoid exposure to house dust mite, such as covers for mattresses
and bedding, increased or high-quality vacuuming of carpets and mattresses, or sprays that kill the mites, could lessen the severity of
eczema for those who are sensitive to house dust mite. In this review, we aimed to assess the effects of all house dust mite reduction
and avoidance measures for the treatment of eczema.
Review question
Do house dust reduction and avoidance measures provide a successful way to treat eczema?
Study characteristics
We found seven randomised controlled trials, which included 324 adults and children with eczema. We conducted the search up to
14 August 2014. Two of the seven trials included only children; four included children and adults; and one only included adults. Four
of the seven trials compared treatments made up of multiple different house dust mite reduction and avoidance measures, and three
trials tested a single treatment. The treatments were compared against other house dust mite reduction or avoidance treatments, no
treatment, a placebo intervention (e.g., cotton bed covers), or standard care only.
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Key results
We did not find any evidence to inform clinical practice. Some small treatment responses reported were in people with atopic eczema
who were sensitive to one or more airborne allergens. We found no evidence of benefit in the other six included studies. Therefore,
their use in the eczema population as a whole is unknown. High-quality longer trials of single, easy-to-use house dust mite reduction
or avoidance measures should be performed.
Quality of the evidence
These seven very low-quality (Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach) small
trials do not provide enough evidence to recommend any of the house dust mite reduction and avoidance measures tested.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
House dust mite reduction and avoidance measures for treating eczema
Patient or population: children and adults with eczema with proven sensitivity to house dust mite
Settings: participant’s home
Intervention: active
Comparison: control
Outcomes Number of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Clinician-assessed global
eczema severity using a named
scale (Leicester Sign Score)
86 (1) ⊕©©© very lowa Oosting 2002¹
Clinician-assessed global
eczema severity using a named
scale (SASSAD)
60 (1) ⊕©©© very lowb Tan 1996²
Clinician-assessed global
eczema severity using a named
scale (SCORAD)
61 (2) ⊕©©© very lowc Gutgesell 2001³; Ricci 2000
Participant- or caregiver-as-
sessed eczema-related quality of
life (named instrument)
0 (0) N/A -
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
aReasons for a rating of very low quality: moderate proportions of participants not analysed (losses to follow up); not clear whether the
severity of eczema outcome assessors were blinded or not; severity of eczema was not analysed between treatment groups; the total
Leicester Sign Score (LSS) data not reported, including no analyses.
bReasons for a rating of very low quality: big differential in the proportions of participants who were not included in the analyses, small
numbers of participants, baseline severity scores are very different, with the active treatment group having a higher baseline severity and
it is unclear whether this was adjusted for in the analyses.
cReasons for a rating of very low quality: differences in baseline severity, with the active group being more severe, for which it is unclear
whether this was adjusted for in the analyses; small numbers of participants in both trials.
¹Oosting 2002
Active interventions: mite impermeable encasings for mattress, pillow, and duvet.
Control interventions: mite permeable encasings for mattress, pillow, and duvet.
Results: active treatment group (LSS disease activity 17 (6 to 60) to 13 (0 to 55), P = 0.017) (LSS extent 19.5 (3 to 88) to 14.5 (0 to
87), P = 0.038) (LSS itching score mm 73.5 (0 to 100) to 63 (4 to 100), P = 0.045), but did not report the total LSS scores. The trial
report mentioned that there were no significant between-group differences, but did not report any more detail.
²Tan 1996
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Active interventions: mite impermeable encasings, acaricide spray on carpets, and high-filtration vacuum cleaner.
Control interventions: mite permeable encasings, water with a trace of alcohol spray on carpets, and standard-filtration vacuum cleaner.
Results: mean differences in the mean severity scores were -12.6 in the active treatment group and -4.2 in the control group. The
analysis of the differences in the reduction in severity scores between groups used analysis of covariance with initial eczema scores and
logs of the initial mattress dust weight and bedroom carpet Der p1 (Dermatophagoides pteronyssinus) concentration as covariates and
reported a mean difference of 4.2 (95% confidence interval (Cl) 1.7 to 6.7), P = 0.008 (unpaired student’s t-test) in favour of the GORE-
TEX® bedding system, benzyltannate spray, and high-filtration vacuuming.
³Gutgesell 2001
Active interventions: allergen impermeable encasings, acaricide spray (tannic acid and benzyl benzoate).
Control interventions: allergen permeable encasings, water with a trace of ethanol spray.
Results: no statistically significant difference in reduction of severity after one year (P = 0.901) (non-parametric tests for tests of
repeated measures) between the treatment groups. The active encasings group had a reduction in SCORing Atopic Dermatitis (SCORAD)
from a median (interquartile range) of 46 (37 to 55) to 40 (32 to 63), and the control encasings had a change from 35 (24 to 46) to 37
(30 to 45). This study did not provide many details; the SCORAD scores were abstracted from a graph.
Ricci 2000
Active interventions: mite impermeable encasings for mattresses and pillows, weekly hot wash of bedding, frequent vacuuming of living
room and bedroom, soft toys and carpets regularly cleaned or removed, no pets allowed.
Control interventions: no recommendations for changing cleaning patterns given (no treatment).
Results: The reduction in severity was recorded within the group using the dust mite avoidance measures (a reduction from a mean of
33 to 26 SCORAD points) and the group who used normal cleaning patterns (a reduction from a mean of 27 to 24 SCORAD points);
however, the change in severity of eczema was not compared between the two groups.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
B A C K G R O U N D
Description of the condition
Disease definition
Eczema is an inflammatory skin disease that tends to involve flex-
ural skin creases, such as the folds of the elbows or knees. Eczema
is an intensely itchy skin condition, which can relapse and remit
over time (Williams 1994).
Eczema is also often called atopic dermatitis or atopic eczema.
The nomenclature for allergy (Johansson 2001) has been revised
and is now based on the mechanisms by which allergic reactions
are initiated and mediated, although this nomenclature has not
yet been universally adopted. The term atopic eczema can only
be used when sensitisation to common allergens has been verified
by identifying immunoglobulin E (IgE) antibodies in the blood
or by a positive skin prick test (Johansson 2004). We have used
the term eczema in this review throughout to refer to what is
usually described as atopic dermatitis or atopic eczema. We have
only used the terms atopic eczema and atopic dermatitis when
IgE sensitisation has been confirmed. No clinical relevance for
diagnosis between proven atopic eczema and non-atopic eczema
has yet been found (Flohr 2004).
See Figure 1 for an example of this condition.
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Figure 1. Acute atopic eczema in a child. Copyright © 1991 Professor Hywel Williams: reproduced with
permission
Epidemiology and causes
Eczema is a worldwide problem affecting 5% to 20% of children
(Williams 1999). Many of the approximately 2% of adults with
eczema have to cope with a more severe and longer lasting form of
the condition (Charman 2000a). The prevalence of eczema varies
considerably between and within countries (Williams 1999). Of
the children with eczema in the UK under the age of five years
old, around 2% have severe disease, and 84% have mild disease
(Emerson 1998).
Eczema is a complex disease, which probably depends on a com-
plex interaction between several genetic and environmental fac-
tors. Recently, a genetic defect that affects the production of a
key protein for skin barrier function (filaggrin gene mutation)
has been linked to an increased risk of atopic eczema (eczema
with IgE sensitisation) (Muller 2009; van den Oord 2009). Ex-
ternal factors, including house dust mites (Van Bever 2002), mi-
crobes (Bjorksten 2001), climate, stress, and air pollution (Brauer
2007; Penard -Mornard 2005), have all been associated with an
altered risk of developing eczema (Langan 2006). People with se-
vere eczema tend to be sensitive to multiple indoor and outdoor
allergens.
Clinical features
Acute (short-term) eczema often presents as mainly redness, col-
lections of fluid in the top layers of the skin in the form of ’wa-
ter blisters’ (vesicles), and oozing. Chronic (long-term) eczema
has scaling, skin thickening, altered pigmentation, and exagger-
ated surface markings as the predominant signs. Mild eczema of-
ten presents as localised mild scaling, ranging through to severe
eczema, which generally involves the whole body, with redness,
oozing, and secondary infection (Birnie 2008). Eczema mainly af-
fects the flexural creases of the elbows and knees and the face and
neck, although any part of the body can be affected. The main
symptom is itching, which will often lead to a vicious cycle of
scratching, damage, and more itching: the so called “itch scratch
itch” cycle (Bath-Hextall 2008; Boyle 2008).
Natural history
Eczema usually develops early in childhood, with 60% of cases
being seen before the age of one year old and 85% of cases seen
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before the age of five years old (Emerson 2001). The majority
(60% to 70%) of children who have eczema will be clear by 15
years old, although some later relapse. People with eczema are
also more likely to have other atopic diseases, such as asthma,
rhinitis, and food allergy (Beck 2000). The tendency for people
who have or have had eczema to go on to develop asthma and
allergies has become known as the ’atopic march’. Whether this
’march’ from one allergic disease to another exists is the subject of
much speculation (Curtiss 2007; Williams 2006).
Impact
Eczema varies in severity, often from one hour to the next
(Bath-Hextall 2008; Boyle 2008). Chronic sleep disturbance due
to itching and scratching can result in a poor quality of life (Meltzer
2008). The social and emotional impact on the family of a child
with eczema can be in excess of the impact of type I diabetes (Su
1997). Bacterial and viral infections can often present as compli-
cations of eczema (McHenry 1995). A child with eczema can have
their confidence affected by greasy ointmentsmaking the skin look
unsightly and making them less likely to join in with sports or
social events. Adults with eczema often have low self-esteem, and
relationships can be hard to initiate and sustain. Everyday tasks be-
come difficult when the skin of the hands becomes very dry, sore,
and broken. (Bath-Hextall 2008; Boyle 2008). Severe eczema in
childhood may lead to delayed development and puberty (Baum
2002).
Families of people with eczema (Kemp 2003) as well as a country’s
health service can incur substantial economic costs (Mancini 2008;
Verboom2002). Eczemahas been shown tohave similar healthcare
costs to other diseases (Ellis 2002).
Families often pay a large proportion of the costs (some estimates
put this at a third of the total costs for children under five), such
as for special clothing; washing extra laundry; and (especially)
house dust mite control measures, such as mattress protectors (
Emerson 2001). Indirect costs for families are also important, such
as through lost working days when parents are looking after a child
with eczema. The costs to society include the health professional’s
costs; parents who cannot seek employment; and the child who,
as a result of missing school, may face employment limitations (Su
1997).
Description of the intervention
The effectiveness of interventions that reduce or avoid exposure
to house dust mites has been the subject of much uncertainty. A
possible link between reduction of house dust mite exposure and
improvement in asthma has been the subject of intensive research,
but many of the trials have shown conflicting results, and there is
debate about how the evidence should be interpreted (Gotzsche
2008; Platts-Mills 2008). The same effect has been proposed for
eczema, as evidence has shown a link between mite sensitisation,
exposure, and the severity of atopic dermatitis (Mitchell 1982;
Platts-Mills 1983).
House dust mites
There are many different species of mite in house dust; however,
only three of these are very common in homes throughout the
world: Dermatophagoides farinae,Dermatophagoides pteronyssinus,
andEuroglyphus maynei, which are found in temperate climates. In
tropical climates, themite Blomia tropicalis is oftenmore common
(Arlian 2001).
As well as the live mites, their dead bodies and faeces have also
been shown to produce allergic reactions. House dust mites are
dependant on the atmospheric humidity as they are 70% to 75%
water by weight and maintain this by absorbing water from the air
(Arlian 2001). Some of the interventions to reduce their numbers
are therefore aimed at reducing the indoor humidity of dwellings.
See Figure 2 for a picture of a house dust mite.
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Figure 2. A house dust mite. Copyright © 2013 Professor Thomas Platts-Millls: reproduced with permission
Ways to reduce or avoid exposure
There are many different interventions used to attempt to reduce
or avoid exposure to house dust mites, dead or alive, and their
faeces. These can be divided into physical and chemical interven-
tions. Physical interventions include physical barriers (e.g., mat-
tress encasings), reducing indoor relative humidity (e.g., ventila-
tion), changingfloor covering, removing soft furnishings, vacuum-
ing, air filters, ionisers, removal of fluffy or soft toys, heat exchang-
ers, freezing, andwashing (55 degreesCelsius or higher). Chemical
interventions include acaricide sprays (Arlian 2001; Friedmann
1999) and antifungal agents that appear to reduce mite numbers
because of the apparent symbiotic relationship between mites and
fungi (Koren 1993).
Nearly all interventions to reduce or avoid exposure to house dust
mite are used in the home. This effort is usually centred around the
bedroom of the person affected, as a large percentage of house dust
mite exposure is related to close contactwith the bed and associated
bedding. A regimen with many methods may be used, especially
where the house dust mite levels are high or where the person
affected experiences severe allergic reactions (Arlian 2001). The
significance of any exposure to house dust mites outside the home
is not well studied, but is an important consideration, especially as
a large proportion of people with eczema will spend many hours
each week in another environment, such as school or work.
How the intervention might work
As many as a third of people with eczema who have a positive test
for allergy to house dust mite have reported worsening of eczema
or respiratory symptoms when exposed to dust (Hallai 2009). The
research into the relationship between house dust mite allergens
and eczema has a long history. In 1949, Tuft showed that reducing
the levels of house dust mite in the home could benefit people with
eczema (Tuft 1949). The exact mechanism by which exposure to
house dustmite results inworsening of eczema is unclear; however,
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when people with eczema are patch tested with house dust mite,
CD4 positive T cells specific to house dust mite are found in
the patch of skin that has developed eczematous characteristics
(Friedmann 1999; van Reijsen 1992).
Why it is important to do this review
Eczema often follows a chronic, relapsing course (Williams 1994),
and people with eczema frequently end up using many different
topical and sometimes systemic treatments. Some of these treat-
ments, such as topical corticosteroids, have potentially serious side-
effects (e.g., skin thinning), which although they are rare with ap-
propriate treatment, can lead to low levels of treatment compliance
because of an inappropriate level of fear of using the treatment
(Charman 2000b).
Many of the interventions that aim to reduce or avoid house dust
mite exposure often have few or no known adverse effects. In par-
ticular, because of families spending a significant percentage of the
total cost of managing eczema on house dust mite control mea-
sures (Emerson 2001), it is important that the evidence for these
interventions is summarised to highlight any potential benefit or
harm. This will enable people with eczema or their caregivers and
policy-makers to make more informed decisions.
O B J E C T I V E S
To assess the effects of all house dust mite reduction and avoidance
measures for the treatment of eczema.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) that assess the efficacy of
any of the house dust mite reduction and avoidance measures
for the treatment of eczema. We included trials that allowed co-
treatments. We excluded quasi-randomised trials. We would have
included cross-over trials, only if the data at the end of the first
period were available, because of the possibility of treatment carry-
over effects, but we did not identify any for inclusion. We would
have included cluster-randomised trials but identified none for
inclusion.
We excluded trials on house dust mite reduction and avoidance
measures for the prevention of eczema.
Types of participants
Anyone of any age diagnosed with eczema as defined by theWorld
Allergy Organization, or atopic eczema, childhood eczema, or
atopic dermatitis by a clinician. We would have included a diag-
nosis of Besnier’s prurigo or neurodermatitis if there was evidence
of eczema in the flexures before inclusion, but we identified none
for inclusion. We excluded participants with skin comorbidities,
such as psoriasis, ichthyosis vulgaris, or skin infections, including
infected eczema.We accepted diagnosis using theHanifin and Ra-
jka criteria (Hanifin 1980) or the UK diagnostic criteria (Williams
1994).
Types of interventions
All non-pharmacological and pharmacological interventions that
seek to reduce or avoid exposure to house dust mite and their
faeces (which are also allergenic). The comparators were any active
treatment, no treatment, placebo, or standard care only. They are
broadly divided into the following categories.
Educational
• Information on ways to reduce and avoid house dust mite
Environmental manipulation
• Mattress encasings
• Duvet and pillow encasings
• Removal of soft floor covering (e.g., carpets, rugs)
• Vacuuming (e.g., different number of times, higher
filtration)
• Ventilation systems
• Removing people with eczema from their environment for a
defined period (e.g., removing children from a school in a lower
altitude to a school in a high altitude area)
• Ultraviolet C (UVC) light sources
Pharmacological
• Acaricide sprays
Types of outcome measures
Primary outcomes
1. Clinician-assessed global eczema severity using a named
scale (e.g., SCORing Atopic Dermatitis (SCORAD)) or
modification of such a scale.
2. Participant- or caregiver-assessed eczema-related quality of
life using a named instrument.
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Secondary outcomes
1. Participant- or caregiver-assessed global eczema severity
score.
2. Amount and frequency of topical treatment required.
3. Sensitivity to house dust mite allergen using a marker (e.g.,
specific IgE).
4. Adverse effects.
Main outcomes for ’Summary of findings’ table
We have provided data in the ’Summary of findings’ table for the
primary outcome Clinician-assessed global eczema severity using a
named scale (e.g., SCORAD) or modification of such a scale. We
decided that attempting to include only those severity measure-
ments that were validated was too restrictive and that acceptable
validation was difficult to quantify.
Timing of outcome assessment
Short-term outcomes were six months or less, and long-term out-
comes were over six months. Long-term outcomes were of primary
importance because of the need to assess whether the treatment
effects were sustained over a useful length of time for people with
eczema.
Adverse outcomes
We reported all adverse events from the included and excluded
studies and the separate search for rare but potentially serious side-
effects.
Economic data
We did not consider economic factors in this review.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases up to 14 August 2014:
• the Cochrane Skin Group Specialised Register using the
following search terms: ((atopic and dermatitis) or (atopic and
eczema*) or eczema* or neurodermatitis or (infant* and eczema*)
or (child* and eczema*) or (besnier* and prurigo)) AND ((house
and dust and mite*) or (dust and mite*) or (pyroglyphidae or
dermatophagoide* or euroglyphus or blomia));
• the Cochrane Central Register of Controlled Trials
(CENTRAL) (2014, Issue 1), in The Cochrane Library using the
search strategy in Appendix 1;
• MEDLINE via Ovid (from 1946) using the strategy in
Appendix 2;
• Embase via Ovid (from 1974) using the strategy in
Appendix 3; and
• LILACS (Latin American & Caribbean Health Sciences
Literature, from 1982) using the strategy in Appendix 4; and
• The Global Resource of EczemA Trials (GREAT database).
Centre of Evidence Based Dermatology. Accessed at
www.greatdatabase.org.uk on 2 September 2014 using the search
strategy ’house’ OR ’dust’ OR ’mite’ across all fields.
Trials databases
We searched the following trials registers up to 2 September 2014
using the terms ’eczema’ and ’house dust mite’:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The Ongoing Skin Trials Register (www.nottingham.ac.uk/
ongoingskintrials).
Searching other resources
References from published studies
We checked the bibliographies of included and excluded studies
for further references to relevant RCTs.
Unpublished literature
We planned to obtain unpublished ongoing trials information via
correspondence with trial authors.
Conference proceedings
We scanned for further RCTs the abstracts from the International
Research Workshops on eczema and major dermatology and al-
lergy conference proceedings not already recorded in theCochrane
Skin Group Specialised Register.
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Adverse effects
We did not perform a separate search for adverse effects of the
target interventions. We did examine data on adverse effects of all
of the reduction and avoidance measures used for the treatment
of eczema from the included studies.
Data collection and analysis
Selection of studies
Two authors (HN and EP) independently checked the titles and
abstracts identified from the searches.We excluded studies where it
was clear that they did not refer to a randomised controlled trial on
house dustmite avoidance or reductionmeasures for the treatment
of eczema. When it was unclear, then we obtained the full text of
the study,which two authors (HNandEP) independently assessed.
The authors decided which trials fitted the inclusion criteria. A
third author (RB or HW) would have resolved any disagreement
by discussion, but there were no disagreements. We recorded the
reasons for exclusion in the ’Characteristics of excluded studies’
tables.
Data extraction and management
Two authors (HN and EP) independently extracted data using a
specially designed data extraction form and checked and entered
the data into RevMan (Review Manager 2014). Data extracted
included participant numbers, characteristics, interventions, out-
comes, and results. The same two authors resolved discrepancies
between them, with discussion with a third author (RB or HW) if
necessary. We obtained missing data from trial authors where pos-
sible. We were not blinded to the names of trial authors, journals,
or institutions.
Assessment of risk of bias in included studies
The quality assessment included an evaluation of the following
components for each included study, since there is some evidence
that these are associated with biased estimates of treatment effect
(Higgins 2011):
(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - we considered it ’ad-
equate’ if the assignment could not have been foreseen;
(c) who was blinded or not blinded (participants, clinicians, out-
come assessors); and
(d) howmany participants were lost to follow up in each arm (split
into postrandomisation exclusions and later losses if possible) and
whether participants were analysed in the groups to which they
were originally randomised (intention-to-treat).
In addition, we assessed the following:
(e) degree of certainty that participants had eczema;
(f ) baseline comparison for severity of disease;
(g) whether outcomes and any subgroup analyses were clearly de-
fined; and
(h) treatment compliance - whether or not measurements were
taken and, if so, whether they were high.
Measures of treatment effect
Wewere unable to combine any of our results because of variability
in the interventions and paucity of data. If in future updates of
this review it is possible to carry out quantitative analyses, we will
do the following: For dichotomous outcomes, we will express the
results as risk ratios (RR) and 95% confidence intervals (CI); we
will not express these as odds ratios as the event rates are common
and we do not wish to overestimate the treatment effect. We will
express the continuous outcomes as mean differences (MD) and
95% CI. For dichotomous outcomes, we will express the results
as number needed to treat (NNT) with 95% confidence intervals
and the baseline risk to which it applies.
Unit of analysis issues
Cross-over trials
If we had identified cross-over trials, we would have conducted a
paired analysis according to the guidance given in the Cochrane
Handbook for Systematic reviews of Interventions, chapter 16
(Higgins 2011). We would have analysed these trials separately to
the parallel group studies or studies of other designs.
Cluster trials
If we had identified cluster trials, we would have analysed these
appropriately using the interclass correlation coefficient, and we
would have synthesised these with the parallel group.
Within-person trials
If we had identified within-person trials, we would have abstracted
the paired analysis results from the original paper and reported
these. We would have analysed these separately from the parallel
group and cross-over trials.
Multiple treatment group trials
One included trial, Colloff 1989, had more than one active inter-
vention arm. If we had had sufficient numbers of studies to carry
out a meta-analysis, we would have followed the advice in the
Cochrane Handbook for Systematic Reviews of Interventions, chapter
16 (Higgins 2011), and considered, for example, whether any of
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the arms could be sensibly combined, or whether we should in-
clude only the arms which were compatible with other trials.
Dealing with missing data
We contacted study authors for clarification of missing data and
summary statistics.
Assessment of heterogeneity
If we had assessed heterogeneity, wewould have used the I² statistic.
If substantial (I² statistic > 50%)heterogeneity had existed between
trials for any of the outcomes, we would have explored the reasons
for the heterogeneity, such as differences in participant factors or
treatment factors. We described the findings narratively, as it was
not possible to perform a meta-analysis.
Assessment of reporting biases
If we could have pooled together 10 or more studies, we would
have performed funnel plots to assess possible reporting biases.
Data synthesis
If trials with similar types of intervention had been available, we
would have used a fixed-effect model in the first instance and
tested for heterogeneity. We would then have used a random-ef-
fects model for further analyses if we had found significant het-
erogeneity.
Subgroup analysis and investigation of heterogeneity
If the number of studies allowed, we would have explored the
effect of potential confounding variables and effectmodifiers of the
meta-risk estimate using meta-regression methods, including, for
example, severity of eczema, age, length of intervention, sensitivity
to house dust mite allergens, and house dust mite allergen levels
if the appropriate data had been available.
Sensitivity analysis
Wehad planned to explore reasons for heterogeneity between trials
and, if necessary, perform sensitivity analyses examining the effects
of excluding subgroups, such as very low- or low-quality (GRADE)
trials.
R E S U L T S
Description of studies
Results of the search
The searches of the Cochrane Skin Group Specialised Regis-
ter, CENTRAL in The Cochrane Library, MEDLINE, Embase,
LILACS, and GREAT databases retrieved 308 unique records.We
identified one record through searching other sources,making 309
records in total. Of these 309 records, we excluded 290 after scru-
tinising the titles and abstracts. We obtained the full texts of the
remaining 19 records. From these 19 records, we excluded eight
references. The remaining 11 references referred to seven different
studies, which we included (see Figure 3).We did not identify any
studies that needed further information regarding classification or
any ongoing studies.
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Figure 3. Study flow diagram
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Included studies
In this review, we included seven studies of 324 adult and child
participants with eczema. Eleven references reported these seven
studies.
Design
Six out of the seven included studies divided the participants into
two separate groups and performed what was either reported to
be or appeared to be from the description a parallel group study
(Endo 1997; Gutgesell 2001; Oosting 2002; Ricci 2000; Tan
1996; Terreehorst 2005). The remaining study (Colloff 1989) ran-
domised the participants into four groups.
We did not identify any cross-over trials, cluster trials, or within-
person trials.
Sample sizes
All seven included studies were small (Colloff 1989; Endo 1997;
Gutgesell 2001; Oosting 2002; Ricci 2000; Tan 1996; Terreehorst
2005), ranging from 20 to 86 participants per study. Colloff 1989
randomised 23 participants into four groups, resulting in only
four to six participants per group. Eczema is a relatively common
condition, especially in childhood, so it is surprising not to have
found a larger study on house dust mite reduction and avoidance
measures for the treatment of eczema.
Setting
Details about the setting for the use of the interventions in the
studies was very clear and was the same for all seven: The study
interventions were all used in the participant’s own homes.
Five out of the seven studies reported details of the setting of re-
cruitment and the locationof follow-up assessments (Colloff 1989;
Endo 1997; Oosting 2002; Tan 1996; Terreehorst 2005). Four
studies recruited from secondary care, and one study recruited
from both the community (primary care), using an article in the
press, and secondary care (Oosting 2002).
Participants
All of the seven studies gave details about the age of the included
participants, which ranged from two to 65 years old. Two of the
studies were on children from three to 12 years old and two to
10 years old (Endo 1997; Ricci 2000, respectively); one study,
Gutgesell 2001, looked at adults aged 18 to 30 years old; and
four studies looked at children and adults aged seven to 65 years
old (Tan 1996), eight to 50 years old (Oosting 2002; Terreehorst
2005), and 12 to 47 years old (Colloff 1989). All of the seven
studies stated that the participants must have atopic eczema, but
only five studies reported the method of diagnosis (Colloff 1989;
Endo 1997;Oosting 2002; Ricci 2000; Terreehorst 2005); three of
these trials required the participants to fulfil the criteria of Hanifin
and Rajka.
Outcomes
Six of the seven included studies reported outcomes that mea-
sured the severity of eczema (Colloff 1989; Endo 1997; Gutgesell
2001; Oosting 2002; Ricci 2000; Tan 1996), but only four of
them used a named severity scale (SCORAD; Six Area, Six Sign
Atopic Dermatitis (SASSAD); or the Leicester Sign Score (LSS))
(Gutgesell 2001; Oosting 2002; Ricci 2000; Tan 1996). Only one
study (Terreehorst 2005) measured quality of life; however, as this
study used the SF-36 form (which measures generic quality of
life), we could not analyse the data for this review. Four studies
out of the seven measured specific serum IgE to house dust mite
(Colloff 1989; Endo 1997; Gutgesell 2001; Oosting 2002). One
study, Gutgesell 2001, recorded both the amount of topical corti-
costeroids used and participant-rated global eczema severity.
Interventions
Of the seven included studies, four looked at complex house
dust mite reduction and avoidance interventions (Colloff 1989;
Gutgesell 2001; Ricci 2000; Tan 1996), with most interventions
aiming to reduce the numbers of house dust mites. Two stud-
ies studied bedding encasings only (Oosting 2002; Terreehorst
2005), and one study, Endo 1997, compared different levels of
vacuum suction power as the only variable. In total, five of the
seven studies included bedding or mattress encasings as part of a
complex intervention or on their own (Gutgesell 2001; Oosting
2002; Ricci 2000; Tan 1996; Terreehorst 2005). Four studies in-
cluded vacuuming (Colloff 1989; Endo 1997; Ricci 2000; Tan
1996). Three studies looked at the use of mite-killing (acaricide)
sprays, one containing natamycin (Colloff 1989) and the other
two containing tannic acid and benzyl benzoate (Gutgesell 2001;
Tan 1996). One study (Ricci 2000) compared a strict routine of
dust reduction and avoidance measures, which comprised the use
of mattress and pillow encasings, vacuuming of the bedroom and
living room carpets twice a week, other carpets vacuumed once a
week or removed, removal or washing of soft toys once a week,
and hot washing of bedding once a week compared with normal
cleaning habits. Another study, Endo 1997, used some standard-
ised house dust mite reduction measures for both groups.
Excluded studies
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We excluded 290 studies from the review by screening the title
or abstract. Most of these assessed house dust mite reduction and
avoidancemeasures but did not involve peoplewith eczema.Of the
19 full papers that we obtained and scrutinised, we excluded eight.
The reasons for exclusion were as follows: no randomisation, no
comparative intervention, and not testing house dust mite reduc-
tion and avoidance measures (see the ’Characteristics of excluded
studies’ tables).
We eventually excluded Holm 2001 because although the study
fitted all the review inclusion criteria, it did not mention whether
it had randomised the participants. Contact from the authors con-
firmed that they had not randomised participants to treatment
(Acknowledgements). Therefore, we excluded the study.
Risk of bias in included studies
Please see Figure 4 for the ’Risk of bias’ summary. This gives our
judgements about each ’Risk of bias’ item for each included study.
Overall, the included studies have a high risk of bias.
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Figure 4. ’Risk of bias’ summary: review authors’ judgements about each ’Risk of bias’ item for each
included study
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Allocation
None of the seven included studies provided details about the
method of generating the allocation sequence.
Only one of the seven studies, Terreehorst 2005, gave any informa-
tion at all about the concealment allocation sequence. This study
described a process of remote randomisation and dispensing of the
intervention to the participants, which makes it highly unlikely
that any of the study personnel or participants could have known
or predicted the allocation sequence. With so little information
about the concealment of allocation to treatment for the other
six studies, the risk of selection bias was judged unclear for this
domain.
Blinding
All seven included studies reported that blinding took place; how-
ever, information about the methods of blinding and who were
blinded are all missing or so brief that it was impossible to make
a judgement on the potential for performance bias. Considering
that the participants of the studies nearly always had to perform the
intervention themselves or have encasings on their bed, it would
seem highly unlikely that they were truly blinded in any of the in-
cluded studies, even if this had been attempted. Only three studies
reported that they blinded the person who assessed the eczema
severity outcome to the treatment allocation and therefore had
a lower risk of detection bias (Gutgesell 2001; Ricci 2000; Tan
1996).
Incomplete outcome data
None of the included studies reported using intention-to-treat
principles for the analysis, and four studies reported a lower num-
ber of participants analysed compared with the number of partic-
ipants randomised (Colloff 1989; Endo 1997; Oosting 2002; Tan
1996). Of particular concern was the difference in the number of
withdrawals between the intervention groups in one study (Tan
1996), where 2/30 withdrew from the active intervention group
using mite impermeable encasings, acaricide spray, and high-fil-
tration vacuuming compared with 10/30 for the comparative in-
tervention of cotton encasings, placebo spray, and low-filtration
vacuuming. Only those that completed this study were analysed.
Selective reporting
Most of the trials had a high risk of bias for selective reporting,
such as outcomes not being compared between groups, subgroup
results being given inappropriate prominence, or stated outcomes
not being reported in the results.
Other potential sources of bias
We attempted to contact authors of all the included studies,
but were only successful in obtaining additional information for
Terreehorst 2005 and Tan 1996.
The data on many of the participants in Terreehorst 2005 had
previously been published in 2003, which we listed as a secondary
reference to this included study. This previous trial report had
stated that all participants were encouraged to hot wash the bed-
ding weekly, which could have masked any beneficial effects of the
encasings.
We were able to find additional information about Oosting 2002
in a letter to the editor and a subsequent reply in 2003, which we
listed as secondary references to this included study.
In the trial byColloff 1989, the definitionof eczema ’classic clinical
features and chronic relapsing course of atopic dermatitis’ was very
wide, raising the possibility that not all participants had eczema.
Endo 1997 diagnosed atopic eczema according to the criteria of
Hanifin and Rajka, and baseline severity of eczema was compa-
rable between groups. Gutgesell 2001 did not report any details
of the definition of eczema. Ricci 2000 described the inclusion
criterion as ’the extrinsic variant of AD, i.e. raised serum total IgE
antibodies and/or the presence of specific IgE antibodies to foods
or inhalant allergens’. Tan 1996 did not state the method of di-
agnosis of eczema. It was also stated that there were more partici-
pants with severe eczema in one group than the other. Terreehorst
2005 and Oosting 2002 defined eczema according to the Hanifin
and Rajka criteria.
Effects of interventions
See: Summary of findings for the main comparison
As many of the included studies looked at differing complex in-
terventions, we discuss the results of all the seven included studies
narratively. As none of the studies looked at the same outcomes
for the same or similar interventions, it was not possible to com-
bine studies in a meta-analysis. Four included studies assessed our
primary outcome, ’Clinician-assessed global eczema severity using
a named scale (e.g., SCORing Atopic Dermatitis (SCORAD)) or
modification of such a scale’, and one included study assessed our
primary outcome of ’Participant- or caregiver-assessed eczema-re-
lated quality of life using a named instrument’.
One included study assessed our secondary outcome of ’Partici-
pant- or caregiver-assessed global eczema severity score’. One in-
cluded study assessed our secondary outcome of ’Amount and fre-
quency of topical treatment required’. Four included studies as-
sessed our secondary outcome of ’Sensitivity to house dust mite al-
lergen using a marker (e.g., specific IgE)’. We did not find any ad-
verse events associated with house dust mite reduction and avoid-
ance methods in the included studies, so we could not address our
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secondary outcome of ’Adverse effects’.
Primary outcomes
Clinician-assessed global eczema severity using a named
scale (e.g., SCORing Atopic Dermatitis (SCORAD)) or
modification of such a scale
Two studies measured the severity of eczema using SCORAD.
Gutgesell 2001 found no statistically significant difference in re-
duction of severity after one year (P = 0.901) (non-parametric tests
for tests of repeated measures) between the use of allergen imper-
meable polyurethane encasings and acaricide spray consisting of
tannic acid and benzyl benzoate versus allergen permeable cotton
encasings and placebo acaricide spray consisting of water and a
trace of ethanol. The active encasings group had a reduction in
SCORAD from a median (interquartile range) of 46 (37 to 55)
to 40 (32 to 63), and the control encasings had a change in SCO-
RAD from 35 (24 to 46) to 37 (30 to 45). This study did not
provide many details; we abstracted the SCORAD scores from a
graph, and the trial only had 20 participants in total.
The second study by Ricci and colleagues, involving 41 partici-
pants (Ricci 2000), only used comparative groups for two months.
The study recorded reduction in severity within the group using
the dust mite avoidance measures (a reduction from a mean of
33 to 26 SCORAD points) and also the group who used normal
cleaning patterns (a reduction from a mean of 27 to 24 SCO-
RAD points). However, despite measuring the reduction in sever-
ity, there was no comparison between the two groups.
The paper by Friedmann and colleagues, which was an additional
report of the included study by Tan and colleagues involving 60
participants (Tan 1996), reported eczema severity over six months
measured using the Six Area, Six Sign Atopic Dermatitis (SAS-
SAD) severity scale, which runs from 0 to 108. A significant bene-
fit for a complex intervention of a GORE-TEX® bedding system
combinedwith benzyltannate spray andhigh-filtration vacuuming
was reported. Themean difference in themean severity scores were
-12.6 in the active treatment group and -4.2 in the control group.
The analysis of the differences in the reduction in severity scores
between groups used analysis of covariance with initial eczema
scores and logs of the initial mattress dust weight and bedroom
carpet Dermatophagoides pteronyssinus (Der) p1 concentration as
covariates and reported a mean difference of 4.2 (95% confidence
interval (Cl) 1.7 to 6.7), P = 0.008 (unpaired student’s t-test), in
favour of the GORE-TEX® bedding system, benzyltannate spray,
and high-filtration vacuuming.
The trial by Oosting and colleagues, involving 86 participants
(Oosting 2002),measured eczema severity using the Leicester Sign
Score (LSS) (median and range) over one year and found signif-
icant reductions in severity, extent, and itching scales of the LSS
within the active treatment group (LSS disease activity 17 (6 to
60) to 13 (0 to 55), P = 0.017) (LSS extent 19.5 (3 to 88) to 14.5
(0 to 87), P = 0.038) (LSS itching score mm 73.5 (0 to 100) to
63 (4 to 100), P = 0.045), but did not report the total LSS scores.
The trial report mentions that there were no significant between-
group differences, but does not report any more detail.
Participant- or caregiver-assessed eczema-related quality of
life using a named instrument
Only one study, involving 64 participants (Terreehorst 2005),
measured quality of life. As a generic self assessment of physical
and emotional health scale, SF-36 was used, which does not specif-
ically ask about eczema-related quality of life; it was not directly
relevant to this review. No significant differences were found be-
tween using mite impermeable encasings or permeable encasings.
Secondary outcomes
Participant- or caregiver-assessed global eczema severity
score
One study, Gutgesell 2001, recorded participant-assessed skin sta-
tus using a visual analogue scale. The study found no significant
statistical difference between allergen impermeable encasings and
acaricide spray consisting of tannic acid and benzyl benzoate com-
pared with allergen permeable cotton encasings and placebo aca-
ricide spray of water with a trace of ethanol. There were only 20
participants. There were no detailed data for this outcome, and
there is not enough information to be sure if the participants were
blinded in the report.
Amount and frequency of topical treatment required
Again, only one study, Gutgesell 2001, recorded the amount of
topical corticosteroid used. This was recorded by weighing the
amount of cream or ointment left in the participant’s steroid con-
tainers at the end of the study. No significant difference was found
between the amount of topical corticosteroid used in each group
(P = 0.624) (exact Wilcoxon test), but the study did not report
detailed data.
Sensitivity to house dust mite allergen using a validated
marker (e.g., specific IgE)
Four of the seven studies assessed sensitivity to house dust mite
using different methods (Colloff 1989; Endo 1997; Gutgesell
2001; Oosting 2002).
One study, involving 23 participants (Colloff 1989), did not anal-
yse between-group differences.Within-group analyses showed sta-
tistically significant reductions in serum house dust mite (Der-
matophagoides pteronyssinus (D. pteronyssinus))-specific IgE for vac-
uuming in combinationwith natamycin treatment (P < 0.05). Vac-
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uuming in combination with placebo treatment also provided sig-
nificant reductions in serum total IgE (P < 0.05) and serum house
dust mite (D. pteronyssinus)-specific immunoglobulin G (IgG) (P
< 0.01) after 12 weeks. Analysis of the treatment effects were car-
ried out using t-tests.
One study, involving 30 participants (Endo 1997), did not find
any significant differences (no between-group statistical tests re-
ported) between the intervention groups, which compared full
power vacuuming against half power vacuuming for both total and
house dust mite (D. pteronyssinus and Dermatophagoides farina)-
specific IgE levels after one year.
Oosting 2002, which included 86 participants, did not show any
significant difference between the intervention groups for house
dust mite-specific IgE levels after one year (-2.15, -58.5 to 44.6
for placebo compared with -2.15, -30.2 to 33.9). No statistical
comparison between the groups was reported, but the difference
was described as not significant. The final study, involving 20
participants (Gutgesell 2001), also did not find any significant
difference in the house dust mite-specific IgE levels (statistical data
were not reported) between the intervention groups after one year.
Adverse effects
None of the seven included studies reported recording adverse
events. We managed to contact one author, who confirmed that
no adverse events related to the use of encasings had occurred.
D I S C U S S I O N
Summary of main results
The small amount of data on the severity of eczema measured us-
ing SCORAD in two studies do not present any evidence for a sig-
nificant benefit of the use of mite impermeable mattress encasings
and acaricide spray over placebo (mite permeable encasings) and
house dust mite reduction-cleaning practices compared with nor-
mal cleaning patterns. One study, involving 60 participants (Tan
1996), which measured the change in eczema severity using SAS-
SAD over six months, found a modest but statistically significant
benefit of a GORE-TEX® bedding system combined with ben-
zyltannate spray and high-filtration vacuuming. This study also
reported a 98% reduction in the number of mites in the active
treatment group.
None of the included studies reported investigator-assessed global
measures of eczema severity. There were little data on participant-
assessed eczema severity, with one small study of 20 participants,
Gutgesell 2001, finding no significant difference between allergen
impermeable encasings and acaricide spray versus placebo (cot-
ton encasings and water spray with a trace of ethanol) after two
months.
There is no evidence of benefit through reduction in sensitivity
to house dust mite, with four studies (159 participants) finding
no significant difference in the level of sensitisation to house dust
mite between treatment groups. Two out of four trials did not
statistically compare the results between treatment groups for this
outcome.
None of the included studies looked at eczema-related quality of
life.
Overall completeness and applicability of
evidence
All the included studies found for this review are lacking some
information about trial methodology and detailed data for some
of the reported outcomes, especially numbers of participants in-
cluded in the analyses. Several did not compare the outcome data
between the two treatment groups, leaving readers guessing as to
the clinical meaning of the results. The relevance of the change in
level of house dust mite sensitivity levels in individuals compared
with clinical benefits is obscure.
Quality of the evidence
Nearly all of the included studies were for an unacceptably short
period of time for a long-term chronic condition like eczema.
However, as theyweremostly investigating interventions with pre-
vious evidence of benefit in eczema, it is likely that only short-
term studies would have received ethical approval. There is mostly
not enough detail about the interventions carried out to reproduce
them, and for most of the trials, there was not enough information
about the study population, especially in terms of the details of
the eczema diagnosis and severity. Collectively, these factors mean
that the evidence is of very low quality. Although the small studies
in this review do not seem to provide much evidence to suggest
that house dust mite reduction has any beneficial effect on eczema
or atopic eczema, they also do not provide much evidence of no
benefit. There have not yet been any studies that are both method-
ologically robust and long enough to be reasonably sure of seeing
any beneficial effects, which may be slow to develop.
Potential biases in the review process
We have taken care to try and eliminate bias from this review;
however, it is always possible, although unlikely, that one or more
trials have been missed, buried in journals not covered by the
review search or buried in a journal’s correspondence section.With
such little data in the review at present, any missing trials have a
greater potential to change the review conclusions.
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Agreements and disagreements with other
studies or reviews
Three clinical guidelines and two systematic reviews have looked
at whether house dust mite reduction and avoidance measures are
effective for the treatment of eczema (AAD 2003; Hoare 2000;
Langan 2006; NICE 2007; SIGN 2011). A review of the poten-
tial ’flare factors’ for eczema, Langan 2006, briefly summarised
the RCTs that have assessed the efficacy of house dust mite reduc-
tion and avoidance measures. This review concluded that there
was not enough high-quality evidence to determine whether house
dust mite reduction and avoidance measures are effective. The
NICE guidelines concluded that there was some evidence of ben-
efit from house dust mite reduction measures in adults and chil-
dren after two to six months of treatment (NICE 2007), although
it does point out that there is still room to ask about both the
effectiveness and cost-effectiveness of such intensive interventions
given the potential degree of clinical improvement. The American
Academy of Dermatology (AAD) technical report summarised tri-
als of house dustmite reduction (AAD 2003), andAADguidelines
based on the technical report (Hanifin 2004) stated that there was
not enough evidence to make recommendations about avoidance
of house dust mite. The systematic review byHoare and colleagues
reported that the small, poorly reported trials found did not pro-
vide any convincing evidence about reduction of house dust mite
measures and recommended pragmatic single intervention trials
for future research (Hoare 2000).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There can be little confidence in the observed beneficial effect on
severity of eczema (measured using SASSAD) in one small, very
low-quality (GRADE approach) trial. As this treatment response
has only been seen in those with atopic eczema, with specific sen-
sitivity to one or more aeroallergens, its use in the eczema popu-
lation as a whole is unknown. This trial also reported a high re-
duction in the level of mites in the treatment group, which agrees
with suggestions from trials in allergic rhinitis (Nurmatov 2012):
that it is only a very significant eradication of house dust mites
that produces a clinically significant effect for eczema. The poten-
tial benefit from a small magnitude of effect needs to be weighed
against the impact of sustaining the intervention regimen over
long periods of time.
As none of the trials included in this review measured participant-
or physician-assessed eczema-related quality of life, there is cur-
rently no evidence about the impact of house dust mite reduction
and avoidance measures on people with eczema.
As many as a third of people with eczema who have a positive
test for allergy to house dust mite have reported worsening of
eczema or respiratory symptoms when exposed to dust. Four trials,
three of which had atopic participants and a fourth that did not
require sensitivity to allergens as an inclusion criterion, did not
find any evidence of a reduction in the specific sensitivity to house
dust mites over one year. This evidence hints that a ’home only’
approach to dust mite eradication or reduction is ineffective with
regard to the reduction of sensitivity to house dust mite in the
eczema population. It is also not clear whether this reduction in
a positive reaction to a skin prick test is a poor predictor of a
clinically relevant allergy to house dust mite.
Many of the included trials used multiple different interventions
simultaneously; however, the separate tasks themselves were not
particularly onerous. It is plausible that familieswould bewilling to
use these interventions to see improvements in eczema.Where the
interventions are particularly complex or intensive for parents and
carers, there is potential for difficulties, such as lack of compliance
and pressure on time, finances, and emotional energy.
The evidence available for house dust mite reduction and avoid-
ance measures falls far short of a basis for influencing clinical prac-
tice.
Implications for research
No significant clinical benefit of any house dust mite reduction
or avoidance interventions lasting long enough to be satisfactory
to those with a long-term chronic condition such as eczema has
yet been shown. The included studies have so far lacked method-
ological clarity, which leads to a lack of certainty about the mod-
est positive results shown. Any future trials on reduction of house
dust mite need to address the impact on eczema-related quality
of life. Future trials on reduction or avoidance of house dust mite
for treating eczema are worth pursuing. Such trials should test a
clearly reported single intervention against an appropriate com-
parator, such as a standard care package, only in order to be clear
about which of the many candidate interventions are worth test-
ing further. The eczema trial populations should be well charac-
terised, and trials should provide at least a year of treatment with
additional long-term follow up.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Colloff 1989
Methods Randomised parallel group (4-arm)
Participants Inclusion criteria
• people with clinical features and chronic, relapsing course of atopic dermatitis
• with a positive immediate skin prick response to house dust mite extract
• confirmed positive by RAST to anti-HDM
• elevated total IgE
The study randomised 23 participants, but did not report how many were randomised
to each group
Interventions • only in bedrooms, only 1 pillow per bed - vacuuming of upper surfaces of
mattress and both sides of the pillow just before natamycin spray; natamycin spray
(625 mg for a single bed, 1250 mg for a double bed) on upper surfaces of mattresses
and both sides of the pillow; placebo
• The combinations of interventions in the 4 arms of the trial were as follows:
natamycin and vacuuming; natamycin and no vacuuming; placebo spray and
vacuuming; placebo spray and no vacuuming
Duration: 4 months
Outcomes • Eczema severity (scale not named or validated)
• RAST for IgE or IgG to house dust mite (D. pteronyssinus)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study gave no details beyond “randomly al-
located”
Allocation concealment (selection bias) Unclear risk The study gave no details about whether this was
done
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study provided no details about the blinding
of participants or personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study gave no details about the blinding of
outcome assessments
Incomplete outcome data (attrition bias)
All outcomes
High risk The study did not include participants who with-
drew in the final analysis. (20/23participantswere
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Colloff 1989 (Continued)
included in the analysis: natamycin and vacu-
uming group = 6; natamycin and no vacuuming
group = 4; placebo spray and vacuuming group =
5; placebo spray and no vacuuming = 5)
Selective reporting (reporting bias) Unclear risk There were no details of any prespecified out-
comes reported
Other bias High risk The definition of eczema, ’classic clinical features
and chronic relapsing course of atopic dermatitis’,
was very wide, raising the possibility that not all
participants had eczema
Endo 1997
Methods Randomised, blinded parallel group (2-arm), single-centre
Participants Inclusion criteria
• children with moderate stable atopic eczema based on the Hanafin and Rajka
criteria for more than 1 month
• a positive (more than class 2) RAST to house dust mite
The study randomised 30 participants in total
Interventions • full power vacuuming (n = 15) versus low power (40% to 55% of full power)
vacuuming (n = 15) of floors, quilt covers, and mattresses performed every day by the
participants and every 3 weeks by study investigators
Duration: for a period of 1 year
Outcomes • Eczema severity (trial authors’ own scoring system)
• Serum-specific IgE to house dust mite (Der f, Der p)
• Total serum IgE, mite counts in floors, quilts, and mattresses
Notes The report was written in Japanese
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study gave no information about this
Allocation concealment (selection bias) Unclear risk The study gave insufficient details
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The report stated that the doctors and par-
ticipants did not know to which group the
participants were allocated
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Endo 1997 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study gave no details
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study did not include in the analyses
outcome data for 2/30 (7%) participants
lost to follow up
Selective reporting (reporting bias) High risk The study did not compare the data from
the groups, only the data within each group
Other bias Low risk The study diagnosed atopic eczema accord-
ing to the criteria of Hanifin and Rajka;
baseline severity of eczema was comparable
Gutgesell 2001
Methods Randomised parallel group (2-arm)
Participants Inclusion criteria
• aged 18 to 30
• moderate to severe atopic eczema (method of diagnosis not stated)
• positive RAST class 3 or above
• specific IgE to Der p
• more than 2 mg per g of dust in the mattress
The study randomised 20 participants in total
Interventions • allergen impermeable polyurethane encasings and acaricide spray versus cotton
permeable encasings and water spray with traces of ethanol
The study did not report the number of participants randomised to each group
Outcomes • Severity of eczema (SCORAD)
• Participant-assessed skin status (visual analogue scale)
• Specific IgE to Der p
• Amount of corticosteroid used (weight of treatment tubes)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study gave no information about the gener-
ation of the randomisation sequence
Allocation concealment (selection bias) Unclear risk The study gave no information about conceal-
ment of the allocation sequence
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Gutgesell 2001 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk There were no details about who was blinded,
except for the evaluating physician
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The evaluating physician was not aware of the
allocation of treatment to the participants
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants completed the study and were in-
cluded in the analysis
Selective reporting (reporting bias) Low risk All planned outcomes had their results reported
Other bias Unclear risk The study reported no details of the definition of
eczema
Oosting 2002
Methods Randomised parallel group (2-arm)
Participants Inclusion criteria
• atopic eczema diagnosis according to criteria of Hanifin and Rajka
• 0.7 or above RAST for house dust mite, skin test index, or both
• 200 ng per gram or over of dust in the mattress (Der p1 or Der f1)
The study randomised 86 participants to treatment
Interventions • GORE-TEX® bedding system (mattress, pillow, and duvet encasings), placebo
(cotton) bedding system (mattress, pillow, and duvet encasings)
• The frequency with which the interventions were performed was not reported
Duration: The interventions were given for 1 year
Outcomes • Severity of eczema (Leicester Sign Score)
• Participant-assessed itching and sleeplessness (VAS)
• Sensitivity to house dust mite allergen (intradermal test, serum-specific IgE to Der
p1, atopy patch test)
• Total serum IgE
• Total eosinophil count
Notes The study measured levels of dust andDer p1, but they did not appear to be prespecified
outcomes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study gave no information about generation
of the randomisation sequence
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Oosting 2002 (Continued)
Allocation concealment (selection bias) Unclear risk The study reported no information about alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The study gave no information except that the
nurses taking the dust samples were blinded to
treatment allocation. The study stated double-
blind, but did not report details reported
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study gave no information about blinding
the outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk The numbers for the analysis were lower than the
number of participants randomised (73/86 par-
ticipants)
Selective reporting (reporting bias) High risk Placebo outcome changes were greater in some
instances, but the trial report did notmention this
Other bias Low risk Eczema definition was according to the criteria of
Hanifin and Rajka
Ricci 2000
Methods Randomised 2-arm trial (design not clear)
Participants Inclusion criteria
• aged 2 to 10 years
• diagnosed with atopic eczema according to the Hanifin and Rajka criteria
• all had raised total IgE antibodies to food or inhalant allergens or a positive skin
prick test for food or inhalant allergens
The study randomised 41 participants in total
Interventions • 1 group (n = 21) were instructed to clean as per the following list: mattress and
pillow encasings, hot wash of bedding once a week, living room and bedroom
vacuumed at least twice a week, soft toys taken out of the bedroom or washed at least
once a week, carpets vacuumed at least once a week/removed, no pets
• Another group (n = 20) were given no specific instructions for 2 months, then
they were instructed to follow the same protocol as the other group (as above)
Outcomes • Severity of eczema (SCORAD)
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Ricci 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk The study gave no information about gen-
eration of the randomisation sequence
Allocation concealment (selection bias) Unclear risk The study reported no information about
allocation concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk It would probably have been impossible to
blind the participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study blinded investigators doing clin-
ical assessments. The personnel who took
the dust samples were not told about the
trial
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study did not report the final numbers
of participants analysed
Selective reporting (reporting bias) High risk The study did not perform between-group
analyses, only within groups
Other bias Unclear risk The study described the inclusion criterion
as ’the extrinsic variant of AD, i.e. raised
serum total IgE antibodies and/or the pres-
ence of specific IgE antibodies to foods or
inhalant allergens’
Tan 1996
Methods Randomised, blinded parallel (2-arm) group
Participants Inclusion criteria
• atopic eczema
• aged 7 to 65 years
• at least 1 positive immediate response to aeroallergen prick test (Der p1, cat, or
grass)
The study randomised 60 participants in total
Interventions • allergen impermeable GORE-TEX® encasings, a tannic acid and benzoate
acaricide spray and high-filtration vacuum cleaner (n = 30) versus mite permeable
cotton encasings, water with a trace of alcohol spray, and a low-filtration vacuum
cleaner (n = 30)
Outcomes • Severity of dermatitis score (description matched SASSAD, but not named as
such)
• Body surface area affected
Notes -
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Tan 1996 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The study gave no information
Allocation concealment (selection bias) Unclear risk The study gave no information
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The report stated ’double blind’, but gave
no information about whether this in-
cluded participants, personnel (other than
the outcome assessor), or both
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study reported that the evaluating
physician (severity of eczema) was not
aware of the randomisation status of the
participants
Incomplete outcome data (attrition bias)
All outcomes
High risk The study only included in the final anal-
yses participants who finished the study.
Therefore, 28/30 in the mite impermeable
encasing group and 20/30 in the mite per-
meable encasings group were analysed
Selective reporting (reporting bias) High risk The groups differed in severity at baseline,
but this was not really dealt with in the
analysis. The study gavemuchweight to the
results of a subgroup analysis, but it is not
clear whether this was stated a priori. Also,
the study reports analysis of the difference
between groups for this subgroup analysis
as significant, but the confidence interval
crosses 0
Other bias Unclear risk The study did not state the method of di-
agnosis of eczema, but stated there were
more participants with severe eczema in
one group than the other
Terreehorst 2005
Methods Randomised, blinded parallel (2-arm) group
Participants Inclusion criteria
• atopic eczema/dermatitis syndrome diagnosed according to the criteria of Hanifin
and Rajka
• aged 8 to 50
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Terreehorst 2005 (Continued)
• RAST test of 2 or more, intracutaneous skin test of 0.7 of more for house dust
mite, or both
• mattress must contain at least 200 ng Der p1 in a dust sample
The study randomised a total of 64 participants with eczema. It was not clear how many
participants with eczema were in each group
Interventions • mite impermeable encasings for mattress, pillow, and duvet and mite permeable
encasings for mattress, pillow, and duvet
Outcomes • Quality of life (SF 36) generic self assessment of physical and emotional health
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The paper reported no details
Allocation concealment (selection bias) Low risk There was a clear description of a remote
procedure that prevented the physicians
and participants being able to gain access
to or predict the randomisation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The paper provided a descriptionof ’double
blind’, but reported very little detail
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The study blinded the clinician, but did
not provide enough information in the trial
report to assess whether the participants,
who recorded the data for the subjective
outcomes, were also blinded, and because
of the nature of the different interventions,
it seems likely that this was not possible
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk The study analysed only 89/113 and 93/
111 participants from each group and did
not report how many had eczema
Selective reporting (reporting bias) High risk The study did not specify any time periods
for the outcomes, so it is unclear whether
the time period that the study reported for
each of the outcomes matched the original
trial protocol
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Terreehorst 2005 (Continued)
Other bias Low risk The eczema definition was according to the
Hanifin and Rajka criteria
anti-HDM = anti-house dust mite.
Der f/f1 = Dermatophagoides farinae.
Der p/p1 = Dermatophagoides pteronyssinus.
IgE = immunoglobulin E.
IgG = immunoglobulin G.
n = number.
RAST = radioallergosorbent test.
VAS = visual analogue scale.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adham 2011 There was only 1 intervention group
Corver 2006 This was a prevention of eczema study
D’Souza 1973 This review did not cover the intervention of immunotherapy
Holm 2001 The paper did not report this as being randomised, which we confirmed via contact with the senior
author (Annika Scheynius)
Kim 2005 The paper did not report this as being randomised
Norris 1987 The intervention was not reduction or avoidance of house dust mite
Sanda 1992 The paper did not report this as being randomised
Weber-Chrysochoou 2007 This was not a treatment trial
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D A T A A N D A N A L Y S E S
This review has no analyses.
C O N T R I B U T I O N S O F A U T H O R S
Link with editorial base and co-ordination of contributions from co-reviewers (HN)
Draft protocol (HN, with contributions from all)
Run search (HN)
Identify relevant titles and abstracts from searches (HN and EP)
Obtain copies of trials (HN, EP, with contributions from all)
Selection of trials (HN, EP, RB, and HW)
Extract data from trials (HN, and EP)
Enter data into RevMan (HN, and EP)
Carry out analysis (HN, LR, and EP)
Interpret data (HN, EP, RB, LR, and HW)
Draft final review (HN, with contribution from all)
Update review (HN)
Disclaimer
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the
Department of Health, UK.
D E C L A R A T I O N S O F I N T E R E S T
Helen Nankervis: nothing to declare.
Emma V Pynn: nothing to declare.
Robert J Boyle: “I am a co-investigator on a new trial of temperature controlled laminar airflow for treating atopic eczema http:/
/www.hra.nhs.uk/news/research-summaries/temperature-controlled-laminar-airflow-in-severe-paediatric-eczema/. This is an allergen
avoidance study taking place at Imperial College, in children and adolescents with severe eczema.”
Lesley Rushton: nothing to declare.
Hywel C Williams: nothing to declare.
Deanne M Hewson: nothing to declare.
Thomas Platts-Mills: nothing to declare.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The primary outcomes both stated in the protocol that the severity scales used had to be named and validated. The reality is that with
so little data available for the primary outcomes and the difficulty with defining whether an outcome severity scale has been suitably
validated, we removed the requirement for validated severity scales.
In the protocol, we had stated that we would search excluded studies for adverse effects. We removed this statement as by definition,
they would not be relevant for this review.
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